Entrada Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc. (ticker: TRDA) is a clinical-stage biopharmaceutical company listed on the Nasdaq in the United States. Headquartered in Boston, Massachusetts, the company was founded in 2016 and went public in 2021. Its investment case is built around a differentiated scientific platform called EEV, or Endosomal Escape Vehicle, designed to help therapeutic molecules reach intracellular targets that have historically been considered difficult or inaccessible to drug. For French, Belgian, and Swiss investors, Entrada is best understood as a specialist biotechnology name: pre-commercial, innovation-driven, and highly dependent on clinical execution, but with meaningful upside if its platform continues to validate in humans. Entrada’s core business is the discovery and development of next-generation therapies, with a particular focus on rare and severe diseases. The company’s most advanced programs are in neuromuscular disorders, especially Duchenne muscular dystrophy (DMD). Its pipeline includes several exon-skipping oligonucleotide candidates, notably ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51. Entrada is also advancing VX-670 in myotonic dystrophy type 1 (DM1) through a partnership with Vertex, and it has expanded into ophthalmology with ENTR-801, its first ocular clinical candidate for USH2A-related inherited retinal disease. That broader pipeline gives the company more than one shot on goal, while still keeping the strategic focus on difficult-to-treat genetic and neuromuscular diseases. From a competitive standpoint, Entrada operates in a crowded biotech landscape, particularly in DMD, where it faces competition from gene therapy developers, oligonucleotide companies, and other genetic medicine platforms. Its differentiation lies in the EEV platform, which is intended to improve intracellular delivery and potentially enable better pharmacology versus conventional approaches. At the same time, investors should recognize that this remains a high-risk development company: clinical outcomes can be uncertain, regulatory timelines can shift, and additional capital may eventually be required despite the current cash runway. Recent milestones have been important. In May 2026, Entrada reported positive topline data from Cohort 1 of its ELEVATE-44-201 study in DMD, highlighting favorable safety and tolerability together with early functional benefit. The company also stated that its cash resources should fund operations into the third quarter of 2027. In addition, Entrada said it remains on track for further clinical updates on ELEVATE-45-201 and for additional data readouts across its neuromuscular portfolio, while continuing to advance preclinical work in ophthalmology and metabolic disease. For investors monitoring SEC Form 4 insider activity, TRDA remains a classic science-led Nasdaq biotech story: high uncertainty, but with several clinically meaningful catalysts ahead.